A one year, open, prospective study on the role of quarterly intravitreal injections of Lucentis 0,5 mg (ranibizumab) in preventing of delaying progression of radiation retinopathy in eyes treated with Iodine 125 plaque radiotherapy for posterior uveal melanoma</full-title-trial

Trial Profile

A one year, open, prospective study on the role of quarterly intravitreal injections of Lucentis 0,5 mg (ranibizumab) in preventing of delaying progression of radiation retinopathy in eyes treated with Iodine 125 plaque radiotherapy for posterior uveal melanoma</full-title-trial

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinal disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top